Cyclerion Therapeutics, Inc. (NASDAQ:CYCN) Short Interest Down 40.9% in March

Cyclerion Therapeutics, Inc. (NASDAQ:CYCN) saw a significant decrease in short interest in March. As of March 15th, there was short interest totalling 70,800 shares, a decrease of 40.9% from the February 28th total of 119,700 shares. Approximately 3.9% of the company’s shares are short sold. Based on an average daily volume of 1,850,000 shares, the days-to-cover ratio is presently 0.0 days.

Institutional Investors Weigh In On Cyclerion Therapeutics

A hedge fund recently bought a new stake in Cyclerion Therapeutics stock. Renaissance Technologies LLC bought a new position in Cyclerion Therapeutics, Inc. (NASDAQ:CYCN) during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 10,611 shares of the company’s stock, valued at approximately $34,000. Renaissance Technologies LLC owned about 0.39% of Cyclerion Therapeutics as of its most recent SEC filing. 75.62% of the stock is currently owned by institutional investors and hedge funds.

Cyclerion Therapeutics Price Performance

Shares of CYCN stock traded down $0.04 during mid-day trading on Friday, hitting $2.57. The stock had a trading volume of 12,682 shares, compared to its average volume of 1,321,396. Cyclerion Therapeutics has a 12-month low of $1.27 and a 12-month high of $9.47. The firm’s 50-day moving average is $2.95 and its two-hundred day moving average is $2.89. The firm has a market capitalization of $6.96 million, a P/E ratio of -2.11 and a beta of 2.09.

Cyclerion Therapeutics (NASDAQ:CYCN) last issued its quarterly earnings results on Tuesday, March 4th. The company reported $0.22 earnings per share (EPS) for the quarter. The business had revenue of $1.81 million for the quarter.

Cyclerion Therapeutics Company Profile

Cyclerion Therapeutics, Inc, a biopharmaceutical company, develops treatments for serious diseases. It is developing Olinciguat, an orally administered vascular soluble guanylate cyclase (sGC) stimulator, which is in Phase 2 clinical trial to out-license for cardiovascular diseases; and Praliciguat, a systemic sGC stimulator that is licensed to Akebia Therapeutics, Inc for the treatment of rare kidney disease.